BCRX•benzinga•
BioCryst Pharmaceuticals Announced Results From An Interim Analysis Of The Ongoing Apex-p Clinical Trial Evaluating An Oral Granule Formulation Of Once-daily Orladeyo (Berotralstat) In Pediatric Patients With Hereditary Angioedema Aged 2 To <12 Years
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on February 24, 2025 by benzinga